<DOC>
	<DOCNO>NCT00132470</DOCNO>
	<brief_summary>The AXIS study randomize , double-blind , placebo-controlled , dose-escalating phase IIa trial investigate treatment AX200 ( granulocyte-colony stimulating factor ; G-CSF ) acute ischemic stroke . The primary objective present phase IIa study ass safety tolerability AX200 compare placebo subject suffer acute stroke . The secondary objective ass effect AX200 subject outcome comparison placebo .</brief_summary>
	<brief_title>Treatment With AX200 Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<criteria>Stroke onset within 12 hour prior start study agent administration Ischemic stroke middle cerebral artery ( MCA ) territory confirm magnetic resonance imaging ( MRI ) Time interval since stroke onset impossible determine Carotid Tocclusion ( magnetic resonance angiography [ MRA ] ) Subarachnoid hemorrhage Several safety parameter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>